Harrow Taps LogiCare3PL to Expedite Ophthalmic Drug Distribution

OLIVE BRANCH, Miss. – April 14, 2026 – In a strategic move designed to accelerate the delivery of its eye care medications to the U.S. market, ophthalmic pharmaceutical company Harrow, Inc. (Nasdaq: HROW) has selected LogiCare3PL as its new national distribution partner. The agreement, which took effect on February 1, 2026, sees LogiCare3PL managing the complete logistics for Harrow's growing portfolio of vision-focused therapies.

The partnership underscores a critical trend in the biopharmaceutical industry: the increasing reliance on specialized third-party logistics (3PL) providers that can navigate complex supply chains with exceptional speed and precision. For Harrow, this collaboration is pivotal to ensuring its products, which treat conditions from dry eye disease to glaucoma, reach practitioners and patients more efficiently and cost-effectively.

The Speed Advantage in a Regulated Landscape

LogiCare3PL, a BioCare company, distinguished itself by successfully onboarding Harrow's entire product line in a remarkable four-week timeframe. In an industry where logistics implementation can often stretch for months due to stringent regulatory validation and complex system integrations, this rapid execution was a key factor in Harrow's decision. The swift transition ensured business continuity and immediate market readiness for Harrow's therapies.

This speed is not merely a matter of convenience; it represents a significant competitive advantage. The pharmaceutical supply chain is governed by a labyrinth of regulations, including the Drug Supply Chain Security Act (DSCSA) and current Good Manufacturing Practice (cGMP) standards. Furthermore, many advanced therapies, particularly biologics, require unbroken cold chain management—maintaining precise temperatures from warehouse to clinic—to preserve their efficacy. A failure in this chain can result in millions of dollars in lost product and, more critically, delay patient access to essential treatments.

LogiCare3PL's ability to meet these demands while accelerating the timeline points to its specialized focus on emerging and mid-sized biopharmaceutical manufacturers. Kevin Kissling, VP/GM of 3PL Services for LogiCare3PL, commented on the synergy between the two companies. "We are proud to partner with Harrow and support their broad portfolio of ophthalmic disease management solutions," he stated in the original announcement. "Harrow and LogiCare3PL's shared focus on flexibility, customer-centricity, and rapid execution makes this collaboration especially meaningful."

This high-touch service model, which includes both non-title logistics and full 3PL title distribution, allows Harrow to offload the complexities of warehousing, inventory management, and order-to-cash financial services, enabling the company to concentrate on its core mission of developing and commercializing ophthalmic solutions.

A Strategic Play for Ophthalmic Market Share

The partnership is a calculated move in Harrow's broader strategy to solidify its position in the competitive North American ophthalmic market, a sector valued in the tens of billions globally. Harrow has aggressively expanded its portfolio through strategic acquisitions, adding key FDA-approved branded products to its existing offerings. These include VEVYE® for dry eye disease and a suite of five products acquired in 2023, such as TRIESENCE®, a corticosteroid for ocular inflammation.

By building a comprehensive catalog that addresses conditions affecting both the front and back of the eye, Harrow is positioning itself as a one-stop provider for ophthalmologists. However, a diverse portfolio is only effective if its components can reliably get to market. By entrusting its entire U.S. distribution to LogiCare3PL, Harrow gains a streamlined, efficient, and compliant supply chain capable of scaling with its ambitions. This is crucial for competing against larger pharmaceutical players that leverage scale to their advantage and for staying ahead of pricing pressure from generic manufacturers.

The collaboration supports Harrow's direct-sales model, which relies on building strong relationships with physicians. A dependable and rapid supply chain enhances the company's reputation for reliability, ensuring doctors have access to Harrow's products when their patients need them. As Harrow continues to expand its product offerings, the flexible and robust logistics framework provided by LogiCare3PL will be instrumental in supporting future launches and market expansion.

The Growing Reliance on Niche Logistics Experts

The Harrow-LogiCare3PL agreement is a clear illustration of a paradigm shift in pharmaceutical logistics. As drug development pivots towards more complex biologics, personalized medicines, and therapies for rare and ultra-rare diseases, the one-size-fits-all logistics model is becoming obsolete. These high-value, often temperature-sensitive products demand a level of expertise and customization that generalist providers struggle to deliver.

The global pharmaceutical logistics market is projected to grow from approximately $99 billion in 2024 to over $208 billion by 2033, with the temperature-controlled segment driving much of that expansion. With cold chain failures estimated to cost the industry $35 billion annually, the financial and clinical stakes are incredibly high. Consequently, biopharma companies are increasingly outsourcing their supply chain operations to specialized 3PLs that offer deep expertise in areas like cold chain (-80°C to 8°C), regulatory compliance, and data analytics.

LogiCare3PL was launched specifically to serve this niche, focusing on the unique needs of specialty therapies. By providing end-to-end services—from centralized warehousing and time-sensitive logistics to financial services and regulatory support—these partners act as an extension of the manufacturer itself. This trend allows emerging and mid-sized companies like Harrow to access world-class logistics capabilities without the massive capital investment required to build them in-house, leveling the playing field and accelerating innovation across the industry.

This partnership model, built on trust, specialization, and shared goals, is proving essential for navigating the future of healthcare. It ensures that the groundbreaking therapies emerging from research and development can complete the final, critical journey to the patients who await them.